Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myeloid, Acute 36Advanced Solid Tumors 20Myelodysplastic Syndromes 14Carcinoma, Non-Small-Cell Lung 14Breast Neoplasms 13Advanced Solid Tumor 13Recurrence 10Ovarian Neoplasms 8Neoplasms 8Multiple Myeloma 8Leukemia, Myelomonocytic, Chronic 8Triple Negative Breast Neoplasms 7Solid Tumor 6Myeloproliferative Disorders 6Small Cell Lung Carcinoma 5Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Neoplasm Metastasis 5Lymphoma, Large B-Cell, Diffuse 5Lung Neoplasms 5Carcinoma, Hepatocellular 5Advanced Solid Tumour 5Sarcoma 4Melanoma 4Lymphoma, B-Cell 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Advanced Malignant Solid Tumor 4Advanced Lung Cancer 4Squamous Cell Carcinoma of Head and Neck 3

Interventions

Specimen Handling 7Biopsy 6Cyclophosphamide 5ruxolitinib 4Mycophenolic Acid 4Busulfan 4fludarabine phosphate 3fludarabine 3Whole-Body Irradiation 3Tacrolimus 3Melphalan 3Injections 3Decitabine 3Cyclosporine 3Azacitidine 3venetoclax 2decitabine and cedazuridine drug combination 2Sirolimus 2Methotrexate 2Granulocyte Colony-Stimulating Factor 2veliparib 1tocilizumab 1tagraxofusp 1posaconazole 1peginterferon alfa-2b 1onvansertib 1merphos 1iadademstat 1gilteritinib 1fedratinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × Injections × 1 year × Clear all
NCT05038592 2026-04-14

Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
64 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

University of Washington

Phase 2 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT02257138 2025-06-08

Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Completed
30 enrolled 14 charts
MyeloidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡